BIOMAT Database Logo BIOMAT Database Logo

Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. 1992

S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Transfusion Service Department, University Medical School, Kumamoto, Japan.

A chimeric mouse-human antibody (C beta 1) was constructed that recognized the principal neutralizing domain (PND) of human immunodeficiency virus type 1 (HIV-1) gp120. The constant (C) immunoglobulin regions (C gamma 1 and C kappa) of a mouse monoclonal antibody, 0.5 beta, were substituted for the human C gamma 1 and C kappa by recombining the DNA modules encoding variable or C regions. The DNA constructs were then transfected into X63 Ag8.653 myeloma cells. A clone with a high production of the chimeric antibody (C beta 1) was selected. This antibody was tested for its biological activity against HIV-1. It bound to the surface of HTLV-IIIB-infected cells and reacted with gp120/160 with equal affinity and specificity to that of the parental 0.5 beta murine monoclonal antibody in a Western blot assay. Neutralization and/or enhancement of HIV infection were evaluated with C beta 1 and 0.5 beta. Both C beta 1 and 0.5 beta neutralized cell-to-cell infection and cell-free virus infection by HTLV-IIIB. Antibody-dependence enhancement of HIV infection was not observed with either C beta 1 or 0.5 beta in the presence or absence of human complement. Antibody-dependent cell-mediated cytolysis (ADCC) and antibody-dependent complement-mediated cytolysis (ACC) were observed with C beta 1 but not with the parental 0.5 beta. These findings suggest that the neutralizing antibodies to PND may neutralize but not enhance HIV infection. Furthermore, the high levels of ACC and ADCC shown against HIV-infected cells by C beta 1 indicate that the clinical application of such monoclonal antibodies may be possible.

UI MeSH Term Description Entries
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
September 2004, Journal of virology,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans.
March 1993, Journal of virology,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
December 1994, AIDS research and human retroviruses,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immunodeficiency virus type 1 strains.
July 1995, The Journal of general virology,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.
January 1991, Journal of virology,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine.
January 1995, Vaccine,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
June 1988, Journal of virology,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
April 1991, Proceedings of the National Academy of Sciences of the United States of America,
S Matsushita, and H Maeda, and K Kimachi, and Y Eda, and Y Maeda, and T Murakami, and S Tokiyoshi, and K Takatsuki
An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.
October 1995, Journal of virology,
Copied contents to your clipboard!